Prostate cancer immunotherapy at the dawn of the new millennium

Bibliography

• LANDIS SH, MURRAY T, BOLDEN S, WINGO PA: Cancer Statistics, 1999. CA. Cancer J. Clin. (1999) 49:8–31.
   PubMed Web of Science ®Google Scholar
• OH WK, KANTOFF PW: Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol. (1998) 160:1220–1229.
   Google Scholar
• MERRILL RM, WEED DL, FEUER EJ: The lifetime risk of developing prostate cancer in white and black men. Cancer Epid. Biomark. Prey. (1997) 6:763–768.
   PubMed Web of Science ®Google Scholar
• DAWSON NA: Response criteria in prostatic carcinoma. Semin. Oncol. (1999) 26:174–184.
   PubMed Web of Science ®Google Scholar
• BUBLEY GJ, CARDUCCI M, DAHUT W et al.: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommen-dations from the prostate-specific antigen working group. J. Clin. Oncol. (1999) 17:3461–3467.
   PubMed Web of Science ®Google Scholar
• LOGOTHETIS CJ: Introduction: a therapeutically relevant framework for the classification of human prostate cancer. Semin. Oncol. (1999) 26:369–374.
   PubMed Web of Science ®Google Scholar
• LIPPONEN P, VESALAINEN S, KASURINEN J, ALA-OPAS M,SYRJANEN K: A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour. Anti Cancer Res. (1996) 16:2095–2100.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, SLACK NH: Response criteria for theprostate of the usa national prostatic cancer project. Prostate (1980) 1:375–382.
   PubMedGoogle Scholar
• RAGDE H, ELGAMAL AA, SNOW PB et al.: Ten-yeardisease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma. Cancer (1998) 83:989–1001.
   PubMed Web of Science ®Google Scholar
• TAYLOR CD, ELSON P, TRUMP DL: Importance of continued testicular suppression in hormone-refractory prostate cancer. J. Clin. Oncol. (1993) 11:2167–2172.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, VOGELZANG NJ: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol. (1997) 15:382–388.
   PubMed Web of Science ®Google Scholar
• GARNICK MB, FAIR WR: Combating prostate cancer. Sci.Am. (1998) 279:74–83.
   PubMed Web of Science ®Google Scholar
• HORTON J, ROSENBAUM C, CUMMINGS FJ: Tamoxifen inadvanced prostate cancer: an ecog pilot study. Prostate (1988) 12:173–177.
   PubMed Web of Science ®Google Scholar
• BUBLEY GJ, BALK SP: Treatment of metastatic prostatecancer, lessons from the androgen receptor. Hematol. Oncol. Clin. North Am. (1996) 10:713–725.
   PubMed Web of Science ®Google Scholar
• BONKHOFF H, FIXEMER T, HUNSICKER I, REMBERGER K:Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol. (1999) 155:641–647.
   PubMed Web of Science ®Google Scholar
• MIKKOLA AK, RUUTU ML, ARO JL, RANNIKKO SA, SALOJO: Parenteral polyoestradiol phosphate vs. orchidec-tomy in the treatment of advanced prostatic cancer. efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. finnprostate group. Br. J. Urol. (1998) 82:63–68.
   Google Scholar
• SMITH DC, REDMAN BG, FLAHERTY LE, LI L, STRAWDERMAN M, PIENTA KJ: A phase II trial of oral cliethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology (1998) 52:257–260.
   PubMed Web of Science ®Google Scholar
• AHMED M, CHOKSY S, CHILTON CP, MUNSON KW, WILLIAMS JH: High dose intravenous oestrogen (fosfes-troll) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate. Int. Urol. Nephrol. (1998) 30:159–164.
   PubMedGoogle Scholar
• VOGELZANG NJ: One hundred thirteen men with hormone-refractory prostate cancer died today./ Clin. Oncol. (1996) 14: 1753-1755.
   Google Scholar
• DIPAOLA RS: Approaches to the treatment of patientswith hormone-sensitive prostate cancer. Semin. Oncol. (1999) 26:24–27.
   PubMed Web of Science ®Google Scholar
• BURNET FM: Immunological surveillance in neoplasia. Transplant Rev. (1971) 7:3–25.
   PubMedGoogle Scholar
• BURNET FM: Immunological aspects of malignant disease. Lancet. (1967) 1:1171–1174.
   PubMed Web of Science ®Google Scholar
• SCHIRRMACHER V: Tumor vaccine design: concepts, mechanisms and efficacy testing. Int. Arch. Allergy Immunol. (1995) 108:340–344.
   PubMed Web of Science ®Google Scholar
• HELLSTROM I, HELLSTROM KE: Tumor immunology: an overview. Ann. NY Acad. Sci. (1993) 690:24–33.
   PubMed Web of Science ®Google Scholar
• BOON T, VAN DER BRUGGEN P: Human tumor antigens recognized by T lymphocytes. J. Exp. Med. (1996) 183:725–729.
   PubMed Web of Science ®Google Scholar
• RESTIFO NP, SZNOL M: Cancer vaccines. In: Principles &Practice Of Oncology. Devita J, Hellman S, Rosenberg SA (Eds.) Lippincott-Raven, Philadelphia, USA (1997):3023–3043.
   Google Scholar
• SHU S, PLAUTZ GE, KRAUSS JC, CHANG AE: Tumor immunology. JAMA (1997) 278:1972–1981.
   PubMed Web of Science ®Google Scholar
• BODMER WF, BROWNING MJ, KRAUSA P, ROWAN A, BICKNELL DC, BODMER JG: Tumor escape from immune response by variation in HE& expression and other mechanisms. Ann. NY Acad Sci. (1993)690:42–49.
   PubMed Web of Science ®Google Scholar
• RESTIFO NP, ESQUIVEL F, KAWAKAMI Y et al.: Identifica-tion of human cancers deficient in antigen processing. J. Exp. Med. (1993) 177:265–272.
   PubMed Web of Science ®Google Scholar
• •One of the first important studies in the human system demonstrating this type of tumour escape from immune recognition.
   Google Scholar
• HICKLIN DJ, MARINCOLA FM, FERRONE S: HIA Class Iantigen downregulation in human cancers: T-cell irnnaunotherapy revives an old story. Mol. Med. Today (1999) 5:178–186.
   PubMedGoogle Scholar
• GABRILOVICH DI, CORAK J, CIERNIK IF, KAVANAUGH D,CARBONE DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. (1997) 3:483–490.
   PubMed Web of Science ®Google Scholar
• •Initial indication that defects in the ability of dendritic cells to present antigen exist and are strongly implicated in tumour growth and resistance to immunotherpy.
   Google Scholar
• FINKE JH, ZEA AH, STANLEY J et al.: Loss of T-cellreceptor zeta chain and P561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. (1993) 53:5613–5616.
   PubMed Web of Science ®Google Scholar
• RUKAVINA D, LASKARIN G, RUBESA G et al.: Age-relateddecline of perforin expression in human cytotoxic T lymphocytes and natural killer cells. Blood (1998) 92:2410–2420.
   PubMed Web of Science ®Google Scholar
• HROUDA D, DALGLEISH AG: Gene therapy for prostatecancer. Gene Ther. (1996) 3:845–852.
   PubMed Web of Science ®Google Scholar
• RIEGMAN PH, VLIETSTRA RJ, VAN DER KORPUT JA, ROMIJN JC, TRAPMAN J: Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem. Biophys. Res. Commun. (1989) 159:95–102.
   PubMed Web of Science ®Google Scholar
• ALEXANDER RB, BRADY F, LEFFELL MS, TSAI V, CELIS E:Specific T cell recognition of peptides derived from prostate- specific antigen in patients with prostate cancer. Urology(1998) 51:150–157.
   PubMed Web of Science ®Google Scholar
• CORREALE P, WALMSLEY K, NIERODA C et al.: In vitrogeneration of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. (1997) 89:293–300.
   PubMed Web of Science ®Google Scholar
• CORREALE P, WALMSLEY K, ZAREMBA S, ZHU M, SCHLOM J, TSANG KY: Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol. (1998)161:3186–3194.
   PubMed Web of Science ®Google Scholar
• GOTOH A, KO SC, SHIRAKAWA T et al.: Development ofprostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol. (1998) 160:220–229.
   PubMed Web of Science ®Google Scholar
• LATHAM JP, SEARLE PF, MAUTNER V, JAMES ND: Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. (2000) 60:334–341.
   PubMed Web of Science ®Google Scholar
• YU DC, CHEN Y, SENG M, DILLEY J, HENDERSON DR: Theaddition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. (1999) 59:4200–4203.
   PubMed Web of Science ®Google Scholar
• HODGE JW, SCHLOM J, DONOHUE SJ et al.: A recombi-nant vaccinia virus expressing human prostate-specific antigen (PSA): safety and irnmunogenicity in a non-human primate. Int. J. Cancer. (1995) 63:231–237.
   PubMed Web of Science ®Google Scholar
• SANDA MG, SMITH DC, CHARLES LG et al.: Recombinantvaccinia-PSA (prostvac) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 53:260–266.
   PubMed Web of Science ®Google Scholar
• HARRIS DT, MATYAS GR, GOMELLA LG et al.: Immuno-logic approaches to the treatment of prostate cancer. Semin. Oncol. (1999) 26:439–447.
   PubMed Web of Science ®Google Scholar
• MCELRATH MJ: Selection of potent immunological adjuvants for vaccine construction. Sem. Cancer Biol. (1995) 6:375–385.
   PubMed Web of Science ®Google Scholar
• ISRAELI RS, POWELL CT, FAIR WR, HESTON WDW: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. (1993) 53:227–230.
   PubMed Web of Science ®Google Scholar
• •Most of the preliminary characterisation of prostate-specific membrane antigen. Several studies in both cell- and antibody-based immunotherapy using PSMA as a target were facilitated by information provided in this manuscript.
   Google Scholar
• SALGALLER ML, TJOA BA, LODGE PA et al.: Dendritic cell-based irnmunotherapy of prostate cancer. Crit. Rev. Immunol. (1998) 18:109–119.
   PubMed Web of Science ®Google Scholar
• SALGALLER ML, THURNHER M, BARTSCH G, BOYNTONAL, MURPHY GP: Report from the international union against cancer (UICC) tumor biology committee: uicc workshop on the use of dendritic cells in cancer clinical trials. Cancer (1999) 86:2674–2683.
   PubMed Web of Science ®Google Scholar
• HROUDA D, PERRY M, DALGLEISH AG: Gene therapy for prostate cancer. Semin. Oncol. (1999) 26:455–471.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. (1986) 46:5276–5281.
   PubMed Web of Science ®Google Scholar
• CULVER KW, RAM Z, WALLBRIDGE S, ISHII H, OLDFIELD EH, BLAESE RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 256:1550–1552.
   PubMed Web of Science ®Google Scholar
• •Significant early demonstration of the credibility of gene therapy in the treatment of human cancer.
   Google Scholar
• FREEMAN SM, ABBOUD CN, WHARTENBY KA et al.: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. (1993) 53:5274–5283.
   PubMed Web of Science ®Google Scholar
• HERMAN JR, ADLER HL, AGUILAR-CORDOVA E et al.: Insitu gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther. (1999) 10:1239–1249.
   PubMed Web of Science ®Google Scholar
• PAVLOVIC J, NAWRATH M, TU R, HEINICKE T, MOELLINGK: Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated ki-ras(G12v). Gene Ther. (1996) 3:635–643.
   PubMed Web of Science ®Google Scholar
• GAGANDEEP S, BREW R, GREEN B et al.: Prodrug-activated gene therapy: involvement of an immuno-logical component in the 'bystander effect'. Cancer Gene Ther. (1996) 3:83–88.
   PubMed Web of Science ®Google Scholar
• GUMERLOCK PH, POONAMALLEE UR, MEYERS FJ, DEVERE WHITE RW: Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. (1991) 51:1632–1637.
   PubMed Web of Science ®Google Scholar
• SLOVIN SF, KELLY WK, SCHER HI: Immunological approaches for the treatment of prostate cancer. Sem. Urol. Oncol. (1998) 16:53–59.
   PubMedGoogle Scholar
• •Excellent review of current thinking in this arena from one the most respected prostate cancer research groups in the world.
   Google Scholar
• VIEWEG J, ROSENTHAL FM, BANNERJI R et al.: Immuno-therapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. (1994) 54:1760–1765.
   PubMed Web of Science ®Google Scholar
• SANDA MG: Biological principles and clinical develop-ment of prostate cancer gene therapy. Semin. Urol. Oncol. (1997) 15:43–55.
   PubMedGoogle Scholar
• BILBAO G, CONTRERAS JL, GOMEZ-NAVARRO J, CURIEL DT: Improving adenoviral vectors for cancer gene therapy. Tumour Targ. (1998) 3:59–79.
   Google Scholar
• HWANG C, SANDA MG: Prospects and limitations of recombinant poxviruses for prostate cancer immuno-therapy. Curr. op. Mol. Ther. (1999) 1:471–479.
   PubMed Web of Science ®Google Scholar
• LONG L, GLOVER RT, KAUFMAN HL: The next genera-tion of vaccines for the treatment of cancer. Curr. Op. Mol. Tiger. (1999) 1:57–63.
   PubMed Web of Science ®Google Scholar
• SIEMENS DR, AUSTIN JC, HEDICAN SP, TARTAGLIA J, RATLIFF TL: Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model./ Natl. Cancer Inst. (2000) 92:403–412.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ D, GOFF S, BANK A: A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. (1988) 62:1120–1124.
   PubMed Web of Science ®Google Scholar
• HWANG LC, FEIN S, LEVITSKY H, NELSON WG: Prostate cancer vaccines: current status. Semin. Oncol. (1999) 26:192–201.
   PubMed Web of Science ®Google Scholar
• LOPES AD, DAVIS WL, ROSENSTRAUS MJ, UVEGES AJ, GILMAN SC: Immunohistochemical and pharmacoki-netic characterization of the site- specific immunocon-jugate cyt-356 derived from antiprostate monoclonal antibody 7e11-05. Cancer Res. (1990) 50:6423–6429.
   PubMed Web of Science ®Google Scholar
• HOROSZEWICZ JS, KAWINSKI E, MURPHY GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. AntiCancer Res. (1987) 7:927–936.
   PubMed Web of Science ®Google Scholar
• •Identification and characterisation of the first generation of anti-PSMA antibodies, several of which are currently in pre-clinical development or clinical trial.
   Google Scholar
• MURPHY GP, MAGUIRE RT, ROGERS B eta/.: Comparison of serum PSMA, PSA levels with results of cytogen-356 prostascint scanning in prostatic cancer patients. Prostate (1997) 33:281–285.
   Google Scholar
• CHANG SS, REUTER VE, HESTON WD, BANDER HW, GRAUER LS, GAUDIN PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. (1999) 59:3192–3198.
   PubMed Web of Science ®Google Scholar
• MEREDITH RF, BUESCHEN AJ, KHAZAELI MB et al Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med. (1994) 35:1017–1022.
   PubMed Web of Science ®Google Scholar
• SLOVIN SF, SCHER HI, DIVGI CR eta/.: Interferon-gamma and monoclonal antibody 1311n-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res. (1998) 4:643–651.
   Google Scholar
• MEREDITH RF, KHAZAELI MB, MACEY DJ et al.: Phase II study of interferon-enhanced 13 li-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. (1999) 5:3254S–3258S.
   Google Scholar
• SIMONS JW, MIKHAK B: Ex-vivo gene therapy usingcytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin. Oncol. (1998) 25:661–676.
   PubMed Web of Science ®Google Scholar
• CLARK SC, KAMEN R: The human hematopoietic colony-stimulating factors. Science (1987) 236:1229–1237.
   PubMed Web of Science ®Google Scholar
• RD/AS CI, VERA JC, DELGADO-LOPEZ F et al.: Expressionof granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. Blood (1998) 91:1037–1043.
   Google Scholar
• SALGALLER ML, LODGE PA: Use of cellular and cytokineadjuvants in the inimunotherapy of cancer. J. Surg. Oncol. (1998) 68:122–138.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccinationwith irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539–3543.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, REESE DM, UM B, WHISENANT S, DIXON SC,FIGG WD: Therapy of advanced prostate cancer with granulocyte macrophage colony stimulating factor. Clin. Cancer Res. (1999) 5:1738–1744.
   PubMed Web of Science ®Google Scholar
• SIMONS JW, MIKHAK B, CHANG JF et al.: Induction ofimmunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59:5160–5168.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, MUUL LM et al.: A progressreport on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. (1987) 316:889–897.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: The immunotherapy and gene therapy of cancer. J. Clin. Oncol. (1992) 10:180–199.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANNELLI JR, YANG JC et al.: Treatmentof patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Can. Inst. (1994) 86:1159–1166.
   PubMed Web of Science ®Google Scholar
• SEMINO C, MARTINI L, QUEIROLO P et al.: Adoptiveinimunotherapy of advanced solid tumors: an eight year clinical experience. AntiCancer Res. (1999) 19:5645–5649:
   PubMed Web of Science ®Google Scholar
• CELIS E, TSAI V, CRIMI C et al.: Induction of anti-tumorcytotoxic t lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. (1994) 91:2105–2109.
   PubMed Web of Science ®Google Scholar
• CELTS E, SETTE A, GREY HM: Epitope selection anddevelopment of peptide based vaccines to treat cancer. Sem. Cancer Biol. (1995) 6:329–339.
   PubMed Web of Science ®Google Scholar
• PARKHURST MR, SALGALLER ML, SOUTHWOOD S et al.:Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A.0201 binding residues. J. Immunol. (1996) 157:2539–2548.
   Google Scholar
• •In this report, they demonstrate the promise of using modified peptides that are more immunogenic than - yet cross-react with - their native counterpart. The majority of gp100 peptide-based clinical trials currently underway are utilising these peptide agonists, rather than the native form of the epitope.
   Google Scholar
• SALGALLER ML, MARINCOLA FM, CORMIER JN, ROSENBERG SA: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. (1996) 56:4749–4757.
   PubMed Web of Science ®Google Scholar
• RIDDELL SR, WATANABE KS, GOODRICH JM, LI CR, AGHAME, GREENBERG PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 257:238–241.
   PubMed Web of Science ®Google Scholar
• •Critical study showing that the adoptive transfer of specific T cell clones can produce major clinical impact. This investiga-tion was the basis of numerous clinical trials subsequently undertaken in the fields of infectious disease as well as cancer.
   Google Scholar
• YEE C, GILBERT MJ, RIDDELL SR et al.: Isolation oftyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol. (1996) 157:4079–4086.
   PubMed Web of Science ®Google Scholar
• WATTS C: Capture and processing of exogenous antigens for presentation on MHC molecules. Ann. Rev. Immunol. (1997) 15:821–850.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, CELLA M, DANIELI C, LANZAVECCHIA A:Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. (1995) 182:389–400.
   PubMed Web of Science ®Google Scholar
• •Significant contribution to the field of antigen processing and presentation by dendritic cells.
   Google Scholar
• TJOA B, ERICKSON S, BARREN R, 3RD et al.: In Vitropropagated dendritic cells from prostate cancer patients as a component of prostate cancer immuno-therapy. Prostate (1995) 27:63–69.
   Google Scholar
• MURPHY G, TJOA B, RAGDE H, KENNY G, BOYNTON A:Phase I clinical trial: T-Cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 29:371–380.
   PubMed Web of Science ®Google Scholar
• MURPHY GP, TJOA BA, SIMMONS SJ et al.: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 39:54–59.
   PubMed Web of Science ®Google Scholar
• •First report of treatment benefit in a dendritic cell-based clinical trial of patients with prostate cancer.
   Google Scholar
• SIMMONS SJ, TJOA BA, ROGERS M et al.: GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate (1999) 39:291–297.
   PubMedGoogle Scholar
• SALGALLER ML, LODGE PA, MCLEAN JG et al.: Report of immune monitoring of prostate cancer patients undergoing T- cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate (1998) 35:144–151.
   PubMed Web of Science ®Google Scholar
• PESHWA MV, BENIKE C, DUPUIS M et al.: Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. Cell Transplant (1998) 7:1–9.
   PubMed Web of Science ®Google Scholar
• FONG L, RUEGG CL, BROCKSTEDT D, ENGLEMAN EG, LAUS R: Induction of tissue-specific autoirnmune prostatitis with prostatic acid phosphatase immuniza-tion - implications for immunotherapy of prostate cancer. J. Immunol. (1997) 159:3113–3117.
   PubMed Web of Science ®Google Scholar
• SLOVIN SF, SCHER HI: Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man - clinical trials at Memorial Sloan-Kettering Cancer Center. Semin. Oncol. (1999) 26:448–454.
   PubMed Web of Science ®Google Scholar
• ZHANG S, ZHANG HS, REUTER VE, SLOVIN SF, SCHER HI, LIVINGSTON PO: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. (1998) 4:295–302.
   PubMed Web of Science ®Google Scholar
• FINN OJJEROME KR, HENDERSON RA, PECHER G: Muc-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. (1995) 145:61–89.
   PubMed Web of Science ®Google Scholar
• HO SB, NIEHANS GA, LYFTOGT C et al.: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. (1993) 53:641–651.
   PubMed Web of Science ®Google Scholar
• •Report on the difference in mucin expression between normal and neoplastic tissue. This report demonstrated tumour-specific targets for immunotherapy existed. Moreover, this study was the basis of several clinical trials using MUC-1 and MUC-2 as therapy targets in a wide range of cancers.
   Google Scholar
• BARND DL, LAN MS, METZGAR RS, FINN OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA (1989) 86:7159–7163.
   PubMed Web of Science ®Google Scholar
• AGRAWAL B, KRANTZ MJ, REDDISH MA, LONGENECKER BM: Cancer-associated mud mucin inhibits human T-cell proliferation, which is reversible by 11-2. Nature Med. (1998) 4:43–49.
   PubMed Web of Science ®Google Scholar
• GOYDOS JS, ELDER E, WHITESIDE TL, FINN OJ, LOTZE MT A Phase I trial of a synthetic mucin peptide vaccine, induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. (1996) 63:298–304.
   PubMed Web of Science ®Google Scholar
• AGRAWAL B, GENDLER SJ, LONGENECKER BM: The biological role of mucins in cellular interactions and immune regulation: prospects for cancer irnmuno-therapy. Mol. Med. Today (1998) 4:397–403.
   PubMedGoogle Scholar
• KHANNA R: Tumour surveillance: missing peptides and MHC molecules . Immunol. CellBiol. (1998) 76:20–26.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ NC, LOZIER A, FLAMENT C et al.: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med. (1999) 5:405–411.
   PubMed Web of Science ®Google Scholar
• •Significant study demonstrating the relationship between dendritic cells and NK cells in initiating and maintaining anti-tumour immunity. In addition, the authors increased our understanding of ways in which dendritic cells might overcome one of their greatest theoretical drawbacks: their reliance on MHC expression for naive T cell stimulation.
   Google Scholar